A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
出版年份 2020 全文链接
标题
A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
作者
关键词
-
出版物
LIVER INTERNATIONAL
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-04-24
DOI
10.1111/liv.14490
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Obeticholic acid may increase the risk of gallstone formation in susceptible patients
- (2019) Samer Al-Dury et al. JOURNAL OF HEPATOLOGY
- New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases
- (2019) Sara Lemoinne et al. CURRENT OPINION IN PHARMACOLOGY
- Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis
- (2018) Guido Carpino et al. AMERICAN JOURNAL OF PATHOLOGY
- Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects
- (2018) A. Ahmad et al. JOURNAL OF HEPATOLOGY
- Ductular reaction in liver diseases: pathological mechanisms and translational significances
- (2018) Keisaku Sato et al. HEPATOLOGY
- Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
- (2017) Naoki Ikenaga et al. GUT
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
- (2017) Philipp Schwabl et al. JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- A New Mdr2−/− Mouse Model of Sclerosing Cholangitis with Rapid Fibrosis Progression, Early-Onset Portal Hypertension, and Liver Cancer
- (2015) Naoki Ikenaga et al. AMERICAN JOURNAL OF PATHOLOGY
- TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro
- (2015) Maria Reich et al. GUT
- Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis
- (2015) Zhen-Wei Peng et al. HEPATOLOGY
- The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration
- (2015) Giacomo Lanzoni et al. HEPATOLOGY
- Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
- (2015) Mette Vesterhus et al. HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Bile acids induce hepatic differentiation of mesenchymal stem cells
- (2015) Iris Sawitza et al. Scientific Reports
- The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice
- (2014) TinaMarie Lieu et al. GASTROENTEROLOGY
- Failure of Fibrotic Liver Regeneration in Mice Is Linked to a Severe Fibrogenic Response Driven by Hepatic Progenitor Cell Activation
- (2013) Kaori Kuramitsu et al. AMERICAN JOURNAL OF PATHOLOGY
- Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
- (2013) Len Verbeke et al. HEPATOLOGY
- The TGR5 receptor mediates bile acid–induced itch and analgesia
- (2013) Farzad Alemi et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 −/− (Abcb4 −/− ) mouse cholangiopathy model by promoting biliary HCO 3− output
- (2011) Anna Baghdasaryan et al. HEPATOLOGY
- Increased Activation of the Wnt/ -Catenin Pathway in Spontaneous Hepatocellular Carcinoma Observed in Farnesoid X Receptor Knockout Mice
- (2011) A. Wolfe et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
- (2009) Peter Fickert et al. AMERICAN JOURNAL OF PATHOLOGY
- Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies
- (2009) Yury Popov et al. HEPATOLOGY
- Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
- (2009) Philippe Lefebvre et al. PHYSIOLOGICAL REVIEWS
- Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet
- (2008) B. Kong et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started